Vicore Pharma AB
Karin Eklund Vanderpol is a seasoned professional in regulatory affairs, currently serving as Senior Director of Regulatory Affairs at Vicore Pharma AB since January 2022. Prior to this role, Karin held the position of Head of Regulatory Affairs at Oncopeptides AB from January 2020 to January 2022. Karin's extensive experience in the field includes a significant tenure at Sobi - Swedish Orphan Biovitrum AB (publ), where Karin worked from May 2009 to December 2019, progressing from Senior Regulatory Affairs Manager to Global Regulatory Affairs Director. Karin Eklund Vanderpol's academic background includes a degree from Uppsala University.
This person is not in any teams
Vicore Pharma AB
1 followers
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.